Cancer Research Meeting Calendar Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brehmer, D.
Right arrow Articles by Daub, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brehmer, D.
Right arrow Articles by Daub, H.
[Cancer Research 65, 379-382, January 15, 2005]
© 2005 American Association for Cancer Research

Priority Reports

Cellular Targets of Gefitinib

Dirk Brehmer1, Zoltán Greff2, Klaus Godl1, Stephanie Blencke1, Alexander Kurtenbach1, Martina Weber1, Stefan Müller1, Bert Klebl1, Matt Cotten1, György Kéri2,3, Josef Wissing1 and Henrik Daub1

1 Axxima Pharmaceuticals AG, Munich, Germany and 2 Vichem Chemie Ltd. and 3 Department of Medicinal Chemistry, Peptide Biochemistry Research Group, Semmelweis University, Budapest, Hungary

Requests for reprints: Henrik Daub, Axxima Pharmaceuticals AG, Max-Lebsche-Platz 32, Munich, Germany. Phone:49-89-550-65-356. E-mail: henrik.daub{at}axxima.com.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results and Discussion
 References
 
Targeted inhibition of protein kinases with small molecule drugs has evolved into a viable approach for anticancer therapy. However, the true selectivity of these therapeutic agents has remained unclear. Here, we used a proteomic method to profile the cellular targets of the clinical epidermal growth factor receptor kinase inhibitor gefitinib. Our data suggest alternative cellular modes of action for gefitinib and provide rationales for the development of related drugs.

Key Words: gefitinib • selectivity • proteomics • protein kinases • drug development


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results and Discussion
 References
 
Aberrant activation of the epidermal growth factor receptor (EGFR) tyrosine kinase has been implicated in several key aspects of human neoplasia such as increased proliferation, survival, and invasiveness of cancer cells. In addition, signaling through the EGFR promotes tumor neovascularization and induces resistance to cytotoxic chemotherapy (1). Based on these multiple impacts on cancer cell physiology, the EGFR tyrosine kinase has been recognized as an attractive molecular target for selective treatment of solid tumors with increased EGFR expression levels. The ATP-competitive kinase inhibitor gefitinib (Iressa, ZD1839) was the first EGFR-directed small-molecule drug that received approval for the treatment of non–small cell lung cancer and is now being used as third-line treatment upon failure of established chemotherapies (2). However, an objective tumor response is only observed in a rather small fraction of gefitinib-treated patients. Recently, clinical responses to gefitinib could be correlated with acquired somatic mutations in the kinase domain-encoding region of the EGFR gene, which resulted in enhanced EGFR activity and sensitivity to gefitinib on the target protein level (3, 4). These data indicate that gefitinib is highly efficacious in a subset of patients with lung cancer but have further raised concerns that signaling through overexpressed, nonmutated EGFR in epithelial cancers might not be effectively suppressed up to the maximum tolerated gefitinib dose in a clinical setting (3). In this context, it is also noteworthy that dose escalation from 250 to 500 mg gefitinib per day even somewhat reduced efficacy in patients (2). Furthermore, it is also unclear whether dose-limiting side effects of gefitinib or occasional severe complications such as interstitial lung disease are related to inhibition of either EGFR or unknown secondary targets of the drug (1, 2) .

To address the unresolved issue of possible alternative modes of action and to identify secondary gefitinib targets in addition to the EGFR, we adapted a recently described proteomic approach to study gefitinib selectivity in a cellular system (5, 6). In this report, we describe the identification and characterization of more than 20 previously unknown kinase targets of this clinical EGFR inhibitor.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results and Discussion
 References
 
Compound Synthesis and Immobilization. Gefitinib (Iressa, ZD1839) and 4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-ol were synthesizedas described (7). To prepare AX14596, 0.32 g (1.00 mmol) 4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-ol was refluxed in 20 mL acetonitrile with 0.26 g (1.10 mmol) N-BOC-3-propyl-bromide and 0.15 g (1.10 mmol) potassium carbonate for 8 hours. The reaction mixture wascooled to room temperature, and the solvent was evaporated under reduced pressure. The residue was stirred in a mixture of 15 mL water and 15 mL ethyl acetate for 30 minutes at 0°C. The resulting [3-(4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy)-propyl]-carbamicacid tert-butyl ester was filtered off, washed with 5 mL cold ethyl acetate, and air-dried. Subsequently, 0.25 g (0.50 mmol) of the product were suspended in 20mL methanol, and 1.0 mL ethyl acetate saturated with hydrochloric acid was added to the reaction mixture. After stirring for 2 hours at room temperature and 30 minutes at 0°C, AX14596 (3-[4-(3-chloro-4-fluoro-phenylamino)-7-methoxy-quinazolin-6-yloxy]-propyl-ammonium chloride) was filtered off, washed with 15 mL diethyl ether, and air-dried. The chemical structures of gefitinib and AX14596 were confirmed by nuclear magnetic resonance and the purity of both compounds was more than 95% according to high-performance liquid chromatography-mass spectrometry (MS) analysis.

Covalent coupling of AX14596 to epoxy-activated Sepharose 6B(Amersham, Uppsala, Sweden) and the generation of control beads were done in 50% DMSO/0.05 mol/L Na2CO3 as previously described (5).

Affinity Chromatography and Mass Spectrometry. Affinity chromatography on AX14596 columns was done essentially as previously described for a different kinase inhibitor resin (5). Bound proteins were eluted with lysis buffer containing 1 mmol/L gefitinib, 10 mmol/L ATP, and 20 mmol/L MgCl2 prior to precipitation and subsequent separation by preparative 16-benzyldimethyl-n-hexadecylammonium chloride (16-BAC)/SDS-PAGE followed by matrix-assisted laser desorption ionization MS analysis (5).

For liquid chromatography (LC)-MS/MS analysis, proteins bound to the AX14596 column were first released from the affinity matrix as described above and collected in three fractions followed by a second elution step with buffer containing 0.5% SDS (fraction 4). All fractions were precipitated and resolved by SDS-PAGE over a separation distance of about 20 mm. The gel was stained with Coomassie blue and each of the four lanes of the gel was cut into slices containing no more than 15 visible protein bands. Subsequent tryptic digests, peptide purification, LC-MS/MS analysis, and database searches were done as described (8).

Transfection and In vitro Association Experiments. Cell culture, transient transfection of COS-7 and 293 cells, [32P]Pi labeling, and analysis of cellular Rip-like interacting caspase-like apoptosis-regulatory protein kinase (RICK) activity was done as previously described (5, 9). Breast tumor kinase (BRK) mutants were generated in a pRK-FLAG expression vector (10, 11). Transient transfection of BRK expression constructs into COS-7 cells and subsequent cell lysis and analysis of cellular protein tyrosine phosphorylation was done as described (12).

In vitro Kinase Assays. All kinases were tested in the presence of different gefitinib concentrations, 100 µmol/L ATP, and 1 µCi [{gamma}-32P]ATP at 30°C and substrate phosphorylation was linear with respect to time in all assays. In vitro assays of RICK, p38, cyclin G–associated kinase (GAK), c-jun NH2 terminal kinase 2 (JNK2), casein kinase 1{delta}, and carboxyl-terminal Src kinase (CSK)activities were done as described (5, 12). Activity assays of immunoprecipitated EGFR were done for 10 minutes at the temperature and ATP concentration described above using buffer conditions reported previously (9). Kinase reaction times for the other enzymes tested were 10 [Aurora A, Lyn, Yes, calcium/calmodulin-dependent protein kinase II (CaMKII), EGFR, I{kappa}B kinase {varepsilon} (IKK{varepsilon})], 20 (Met, B-lymphoid tyrosine kinase, Aurora B), or 30 minutes (EphB4) at 30°C. IKK{varepsilon} and BRK were transiently expressed from pRK5-FLAG plasmids in 293 cells and COS-7 cells, respectively (9–11). After cell lysis and immunoprecipitation with anti-FLAG antibody bound to protein G-Sepharose (11), beads were washed thrice with 500 µL lysis buffer without additives and once with 500 µL of the corresponding buffer system [IKK{varepsilon}: 50 mmol/L Tris-HCl (pH 7.5), 10 mmol/L MgCl2, 0.1 mmol/L dithiothreitol, 0.1 mmol/L EGTA; BRK: 50 mmol/L Tris-HCl (pH 7.5), 10 mmol/L MgCl2, 0.1 mmol/L EGTA, 0.8mmol/L MnCl2, 0.1 mmol/L Na3VO4]. All reactions were done in a final volume of 50 µL using 40 µg/mL E. coli–expressed glutathione S-transferase-interferon regulatory factor 3 as kinase substrate for IKK{varepsilon} or 0.5 mg/mL myelin basic protein for BRK. EphB4 (Upstate, Lake Placid, NY) was assayed in the same buffer as BRK with 0.3 mg/mL glyceraldehyde-3-phosphate dehydrogenase as protein kinase substrate. Reactions were stopped by adding SDS sample buffer, samples were separated by SDS-PAGE, and specific substrate phosphorylation was quantified by phosphoimaging. Aurora A (Upstate) and Aurora B (ProQinase, Freiburg, Germany) were assayed in a final volume of 50 µL containing 14 mmol/L 4-morpholinepropanesulfonic acid (pH 7.2), 15 mmol/L MgCl2, 1 mmol/L EGTA, 0.3 mmol/L EDTA, 0.001% Brij-35, 0.5% glycerol, 0.01% 2-mercaptoethanol, 0.1 mg/mL bovine serum albumin, 5 mmol/L ß-glycerophosphate, 0.2 mmol/L Na3VO4, 0.2 mmol/L dithiothreitol, and Kemptide (200 µmol/L) as substrate peptide. B-lymphoid tyrosine kinase and Met (both from Upstate) assays were done in a final volume of 50 µL containing 20 mmol/L Tris-HCl (pH 7.5), 10 mmol/L MgCl2, 1 mmol/L dithiothreitol, 0.01% Brij-35, 0.1 mmol/L Na3VO4, 0.1 mmol/L EGTA and 10 µg poly(Glu4-Tyr). Lyn, HCK, Yes and CaMKII (all from Upstate) were assayed according to the manufacturer's protocols prior to quantification of substrate phosphorylation using Whatman P81 paper. Calculations of all IC50 values were carried out with GraFit software (Erithacus, Horley, Surrey, United Kingdom).


   Results and Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
References
 
Based on earlier structural and medicinal chemistry data, we reasoned that the morpholino group of gefitinib is exposed at the surface of the EGFR kinase domain and therefore synthesized the gefitinib derivative AX14596 with a primary amine at the position of the morpholino function for directed covalent immobilization and the generation of an affinity purification resin with intact, gefitinib-like binding properties (Fig. 1A; refs. 7, 14). Using total cell lysate from 2.5 x 109 HeLa cells as starting material, we then did affinity chromatography on an AX14596 column under optimized biochemical conditions. After sample loading and extensive washing of the column to remove nonspecifically interacting proteins, cellular drug targets were eluted with a combination of ATP and free gefitinib. Subsequently, we separated the ~10,000-fold enriched fraction of cellular gefitinib-binding proteins by two-dimensional 16-BAC/SDS-PAGE (Fig. 1B). MS analysis of the visualized protein spots not only permitted the detection of the EGFR at the expected molecular weight, but, in addition to this internal control, we could also identify additional, putative gefitinib targets such as the protein tyrosine kinases BRK, Yes, CSK, and EphB4 and the serine/threonine kinases RICK (also known as RIPK2, RIP2, and CARDIAK), GAK, CaMKII, Aurora A, JNK2 and p38 (Fig. 1B; Supplementary Table 1). Parallel to the gel-based proteomic approach, we directly digested the purified protein fraction with trypsin and subjected the resulting peptide mixture to LC-MS/MS analysis. The protein identifications from this experimental technique not only included all protein kinases detected in 16-BAC/SDS gels but further added a variety of potential gefitinib targets that included Bub1, integrin-linked kinase, Src family kinases such as Lyn, as well as the receptor tyrosine kinase (RTK) Met (see Supplementary Table 2). In total, more than 20 different protein kinases and various other cellular proteins were identified as putative gefitinib targets by MS analysis (Table 1). Moreover, despite the consistent high gefitinib selectivity for EGFR over closely related RTKs from the same family in vitro, our analysis did not reveal other EGFR-related RTKs such as HER2/ErbB2 as potential gefitinib targets (15). To validate the MS results, we did in vitro binding experiments with control and AX14596 beads in the absence or presence of free gefitinib to verify the specific binding of the identified kinase targets by immunoblot analysis (Table 1; Supplementary Fig. 1). In addition, the sensitivities of the protein kinase targets to gefitinib were assessed in various in vitro kinase activity assays with recombinant enzymes in the presence ofdifferent inhibitor concentrations. The calculation of the drug concentrations required for half-maximal inhibition of kinase activities (IC50) provided a quantitative measure of the differential sensitivities to gefitinib. The IC50 values for all tested kinases are also displayed in Table 1. Interestingly, gefitinib inhibited the serine/threonine kinases RICK and GAK with respective IC50 values of about 50 and 90 nmol/L, showing that these previously unknown gefitinib targets are almost as potently affected by the drug as the tyrosine kinase activity of wild-type EGFR in vitro. In this context, it is noteworthy that gefitinib-responsive lung tumors were found to express EGFR variants with even higher sensitivity for the drug than the wild-type receptor (3, 4). Moreover, we measured IC50 values around 1 µmol/L for various protein tyrosine kinases such as EphB4, BRK, and Lyn, whereas half-maximal inhibition of several other protein kinases tested occurred at higher gefitinib concentrations (Table 1).



View larger version (49K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Identification of cellular gefitinib targets. A, chemical structures of gefitinib compared with AX14596 in its free and immobilized form. B, cellular gefitinib targets from HeLa cells were isolated by affinity chromatography on an AX14596 column and then resolved by 16-BAC/SDS-PAGE. Coomassie-stained protein spots were analyzed by mass spectrometry. The positions of identified protein kinases are indicated. See Supplementary Table 1 for a full list of all identified proteins.

 

View this table:
[in this window]
[in a new window]

  		Table 1. Identification and in vitro characterization of protein kinases targeted by gefitinib

 
To test the potential in vivo significance of our identification ofRICK as a highly sensitive gefitinib target, we did a transfection assay in which a kinase-deficient fragment of RICK served as cellular substrate for coexpressed, catalytically active RICK enzyme (5). Remarkably, pretreatment of cells with 0.3 µmol/L gefitinib already reduced cellular RICK activity by about 50%, indicating that RICK might represent a secondary target during gefitinib therapy (Fig. 2A). Genetic evidence has previously established RICK protein as a mediator of various innate and adaptive immune responses (16). However, it remains to be clarified to which extent RICK kinase activity is involved in these processes and whether RICK kinase inhibition by gefitinib or related inhibitors might have beneficial therapeutic effects in certain states of inflammatory disease. In a second cellular assay, we found that BRK-mediated protein tyrosine phosphorylation was strongly suppressed by low micromolar concentrations of gefitinib in intact cells (Fig. 2B). Importantly, the cytoplasmic tyrosine kinase BRK is frequently overexpressed in carcinomas of the breast and colon and represents a potential target for the treatment of these epithelial cancers (17, 18). Therefore, gefitinib derivatives with increased potency toward BRK could serve as antineoplastic agents directed against a primary molecular target distinct from the EGFR. As previously shown for the EGFR, mutation of a conserved threonine residue at the ATP-binding pocket to methionine also strongly reduced the sensitivities of RICK and BRK to gefitinib inhibition (Fig. 2; ref. 12).



View larger version (51K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Characterization of alternative gefitinib targets in intact cells. A, effect of gefitinib on the kinase activities of wild-type RICK and a partially inhibitor-insensitive RICK-T95M mutant in COS-7 cells, as measured by [32P]Pi incorporation into a cotransfected, kinase-inactive RICK fragment serving as cellular kinase substrate (5). B, COS-7 cells were transiently transfected with constitutively active BRK-Y447F or the derived gefitinib-resistant (BRK-T264M/Y447F) and kinase-deficient (BRK-K219M/ Y447F) mutants as indicated and treated with different gefitinib concentrations for 2 hours prior to cell lysis. Cellular protein tyrosine phosphorylation and BRK expression levels were detected by immunoblot analysis. CTRL, control.

 
Furthermore, our identification of the serine/threonine kinase GAK as one of the most sensitive gefitinib targets points to a previously unrecognized molecular aspect of gefitinib therapy. Recent evidence indicates that GAK acts as a negative regulator of EGFR signaling (19). Although the precise role of GAK kinase activity for the process of EGFR down-modulation remains to be determined, gefitinib-mediated inactivation of a negative regulator would antagonize the inhibitory effect of the drug on EGFR signaling. Therefore, it will be important to find cellular readouts for GAK kinase activity, which permit the quantification of the gefitinib effect on GAK in comparison with dose-dependent EGFR inhibition in the biologically relevant context. In fact, observations consistent with such an undesirable effect of gefitinib downstream of the EGFR have been recently reported (20). In case further investigations establish GAK as a cellular gefitinib target that promotes EGFR downstream signaling in the presence of the drug, it would be highly favorable to select future EGFR-directed drugs for minimal interference with cellular GAK kinase activity.

In conclusion, we have introduced a proteomic method to identify the cellular targets of gefitinib in HeLa cells. The approach is generally applicable and can be expected to reveal even more gefitinib targets when other biological extracts are used as starting materials. The results reported here provide new insights into potential cellular modes of action of gefitinib, which are unrelated to EGFR inhibition, but are relevant for further optimization of gefitinib-like drugs with either the EGFR or various other protein kinases as primary disease targets.


   Acknowledgments
 
Grant Support: German Bundesministerium für Bildung und Forschung.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Jennifer-Ann Ehe for excellent technical assistance, Achim Freisleben for analytical chemistry services, and Gerhard Müller for stimulating discussions.

Received 8/27/04. Revised 11/ 3/04. Accepted 11/11/04.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results and Discussion
 References
 

  1. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003;1:296–313.
  2. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212–8.[Abstract/Free Full Text]
  3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.[Abstract/Free Full Text]
  4. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004:304;1497–500.[Abstract/Free Full Text]
  5. Godl K, Wissing J, Kurtenbach A, et al. An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc Natl Acad Sci U S A 2003;100:15434–9.[Abstract/Free Full Text]
  6. Daub H, Godl K, Brehmer D, Klebl B, Müller G. Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay Drug Dev Technol 2004;2:215–24.[CrossRef][Medline]
  7. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911–4.[CrossRef][Medline]
  8. Wissing J, Godl K, Brehmer D, et al. Chemical proteomic analysis reveals alternative modes of action for pyrido2,3-dpyrimidine kinase inhibitors. Mol Cell Proteomics 2004. Epub ahead of print.
  9. Blencke S, Ullrich A, Daub, H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 2003;278:15435–40.[Abstract/Free Full Text]
  10. Mitchell PJ, Barker KT, Martindale JE, et al. Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene 1994;9:2383–90.[Medline]
  11. Daub H, Blencke S, Habenberger P, et al. Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. JVirol 2002;76:8124–37.[Abstract/Free Full Text]
  12. Blencke S, Zech B, Engkvist O, et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 2004;11:691–701.[CrossRef][Medline]
  13. Peters RT, Liao, SM, Maniatis T. IKK{varepsilon} is part of a novel PMA-inducible I{kappa}B kinase complex. Mol Cell 2000;5:513–22.[CrossRef][Medline]
  14. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265–72.[Abstract/Free Full Text]
  15. Wood ER, Truesdale AT, McDonald OB, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652–9.[Abstract/Free Full Text]
  16. Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 2002;416:194–9.[CrossRef][Medline]
  17. Kamalati T, Jolin HE, Mitchell PJ, et al. Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem 1996;271:30956–63.[Abstract/Free Full Text]
  18. Llor X, Serfas MS, Bie W, et al. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res 1999;5:1767–77.[Abstract/Free Full Text]
  19. Zhang L, Gjoerup O, Roberts TM. The serine/threonine kinase cyclin G-associated kinase regulates epidermal growth factor receptor signaling. Proc Natl Acad Sci U S A 2004;101:10296–301.[Abstract/Free Full Text]
  20. Li B, Chang CM, Yuan M, McKenna WG, Shu HK. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 2003;63:7443–50.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Virol.Home page
E. F. Dunn, R. Fearns, and J. H. Connor
Akt Inhibitor Akt-IV Blocks Virus Replication through an Akt-Independent Mechanism
J. Virol., November 15, 2009; 83(22): 11665 - 11672.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
F. S. Oppermann, F. Gnad, J. V. Olsen, R. Hornberger, Z. Greff, G. Keri, M. Mann, and H. Daub
Large-scale Proteomics Analysis of the Human Kinome
Mol. Cell. Proteomics, July 1, 2009; 8(7): 1751 - 1764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Zannetti, F. Iommelli, R. Fonti, A. Papaccioli, J. Sommella, A. Lettieri, G. Pirozzi, R. Bianco, G. Tortora, M. Salvatore, et al.
Gefitinib Induction of In vivo Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3
Clin. Cancer Res., August 15, 2008; 14(16): 5209 - 5219.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
N. Kumar, R. Afeyan, H.-D. Kim, and D. A. Lauffenburger
Multipathway Model Enables Prediction of Kinase Inhibitor Cross-Talk Effects on Migration of Her2-Overexpressing Mammary Epithelial Cells
Mol. Pharmacol., June 1, 2008; 73(6): 1668 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-C. Wang, S. K. Kulp, D. Wang, C.-C. Yang, A. M. Sargeant, J.-H. Hung, Y. Kashida, M. Yamaguchi, G.-D. Chang, and C.-S. Chen
Targeting Endoplasmic Reticulum Stress and Akt with OSU-03012 and Gefitinib or Erlotinib to Overcome Resistance to Epidermal Growth Factor Receptor Inhibitors
Cancer Res., April 15, 2008; 68(8): 2820 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, and N. T. Ueno
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Mol. Cancer Ther., August 1, 2007; 6(8): 2168 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Takeda, T. Arao, H. Yokote, T. Komatsu, K. Yanagihara, H. Sasaki, Y. Yamada, T. Tamura, K. Fukuoka, H. Kimura, et al.
AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor
Clin. Cancer Res., May 15, 2007; 13(10): 3051 - 3057.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. Wissing, L. Jansch, M. Nimtz, G. Dieterich, R. Hornberger, G. Keri, J. Wehland, and H. Daub
Proteomics Analysis of Protein Kinases by Target Class-selective Prefractionation and Tandem Mass Spectrometry
Mol. Cell. Proteomics, March 1, 2007; 6(3): 537 - 547.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen
Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Saito, H. Hirano, H. Nakagawa, T. Fukami, K. Oosumi, K. Murakami, H. Kimura, T. Kouchi, M. Konomi, E. Tao, et al.
A New Strategy of High-Speed Screening and Quantitative Structure-Activity Relationship Analysis to Evaluate Human ATP-Binding Cassette Transporter ABCG2-Drug Interactions
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1114 - 1124.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. S. Pino, M. Shrader, C. H. Baker, F. Cognetti, H. Q. Xiong, J. L. Abbruzzese, and D. J. McConkey
Transforming Growth Factor {alpha} Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines.
Cancer Res., April 1, 2006; 66(7): 3802 - 3812.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Xue, J. Wyckoff, F. Liang, M. Sidani, S. Violini, K.-L. Tsai, Z.-Y. Zhang, E. Sahai, J. Condeelis, and J. E. Segall
Epidermal Growth Factor Receptor Overexpression Results in Increased Tumor Cell Motility In vivo Coordinately with Enhanced Intravasation and Metastasis
Cancer Res., January 1, 2006; 66(1): 192 - 197.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens
Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R))
Oncologist, September 1, 2005; 10(8): 579 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Godl, O. J. Gruss, J. Eickhoff, J. Wissing, S. Blencke, M. Weber, H. Degen, D. Brehmer, L. Orfi, Z. Horvath, et al.
Proteomic Characterization of the Angiogenesis Inhibitor SU6668 Reveals Multiple Impacts on Cellular Kinase Signaling
Cancer Res., August 1, 2005; 65(15): 6919 - 6926.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brehmer, D.
Right arrow Articles by Daub, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brehmer, D.
Right arrow Articles by Daub, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online